Mark E. Robson, MD

Clinical Laboratory Investigator

Pictured: Mark Robson

Lab Phone


My research is focused on the best ways to use genetic information to improve outcomes of patients with or at risk for hereditary cancers of all types. This includes the integration of genetic testing for both common and rare variants into clinical management, as well as evaluation of the clinical usefulness of genome-wide association studies.

I have played an active role in investigating and assessing cancer risks associated with BRCA mutations, especially those associated with breast and ovarian cancer, and conducting studies to define the clinical behavior and optimal management of individuals carrying BRCA mutations.

I also participate in the development of new treatments, such as PARP inhibitors, which may be particularly useful in people with BRCA mutations.